

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

GROUP: 1625

Antoni TORRENS JOVER, et al.

SERIAL NO: 10/565,979

EXAMINER: O'DELL, DAVID K.

FILED: November 5, 2007

FOR: 2-'4(PHENYLAMINO)-PIPERIDIN-1-YL-N-PHENYL-ACETAMINE
DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5
(NPY5) LIGANDS FOR THE TREATMENT OF OBESITY

RESTRICTION RESPONSE

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

Sir:

In response to the Restriction Requirement dated December 16, 2008, Applicants elect, with traverse, Group I, Claims 1-24, 29 and 30 (drawn to compounds and compositions), for examination.

Additionally, Applicants elect, without traverse and for examination purposes only, the following specie (at least claims 1-24, 29 and 30 readable thereon): N-(9-ethyl-9H-carbazol-3-yl)-2-[4-(2-hydroxymethyl-6-methyl-phenylamino)piperidin-1-yl]acetamide (see for example, compound [1] of claim 24).

Remarks/Arguments begin on page 2 of this paper.